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Objectives We sought to define acute mortality in hospitalized patients undergoing clinically indicated echocardiography
with and without use of an ultrasound contrast agent.
Background The U.S. Food and Drug Administration recently issued a boxed warning and new contraindications for the
perflutren-containing ultrasound contrast agents following post-marketing reports of 4 patient deaths that were
temporally related to Definity (Bristol-Myers Squibb Medical Imaging, Billerica, Massachusetts) administration.
To appreciate the incremental risk of any medical procedure, the ambient risk of untoward outcome in the popu-
lation in question must first be defined. There are no published data on short-term major adverse cardiac events
in hospitalized patients undergoing echocardiography, either with or without administration of an ultrasound
contrast agent.
Methods A retrospective analysis of hospitalized patients undergoing clinically indicated echocardiography between
January 2005 and October 2007, within Saint Luke’s Health System, Kansas City, Missouri, was performed.
Studies were separated into 2 groups, those performed without contrast enhancement (n  12,475) and
those performed with Definity (n  6,196). Vital status within 24 h of the echocardiographic study was
available for all patients using a combination of the Social Security Death Master File and Saint Luke’s
Health System medical records. Incidence of death within 24 h was compared by chi-square test between
Definity and unenhanced procedures.
Results Of the 18,671 patient events, 72 patients died within 24 h. Of those that underwent unenhanced echocardiogra-
phy, 46 died within 24 h (0.37%). Of patients receiving Definity during the echocardiogram, 26 died within 24 h
(0.42%). There was no statistical difference between these 2 groups (p  0.60). No patient died within 1 h of
the echocardiographic study. In a random sampling from the unenhanced (n  201) and Definity groups (n 
202), patients who underwent Definity-enhanced echocardiography exhibited higher clinical acuity, and more
significant comorbidities.
Conclusions Approximately 0.4% of hospitalized patients die within 24 h of echocardiography. There is no increased mortality
risk associated with Definity-enhanced examinations, despite evidence for higher clinical acuity and more comor-
bid conditions in patients undergoing contrast studies. (J Am Coll Cardiol 2008;51:1704–6) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.006p
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Tltrasound contrast agents are indicated to enhance endo-
ardial border delineation in patients with technically diffi-
ult echocardiographic examinations (1) and have proven
tility in the diagnosis and management of critically ill
rom the Saint Luke’s Mid America Heart Institute, Kansas City, Missouri. Dr.
ain has received research support from and has a consultant relationship with
OINT Biomedical, Acusphere, Inc., and Bristol-Myers Squibb Medical Imaging.o
Manuscript received January 16, 2008; revised manuscript received February 26,
008, accepted March 5, 2008.atients (2–4). On October 10, 2007, the U.S. Food and
rug Administration issued new boxed warnings and con-
raindications for the ultrasound contrast agents Optison
GE Healthcare, Buckinghamshire, United Kingdom) and
efinity (Bristol-Myers Squibb Medical Imaging, Billerica,
assachusetts), effectively restricting their use in patients
ith acute coronary syndromes (ACS), worsening or de-
ompensated heart failure (HF), and respiratory failure (5).
hese warnings were largely based on reports of 4 deaths
ccurring during or immediately after Definity injection (5).
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April 29, 2008:1704–6 Ultrasound Contrast Safetylthough these deaths were temporally related to con-
rast use, there is little evidence for causation; a recent
ublication suggested these deaths may have been caused
y “pseudocomplication” (progression of underlying dis-
ase) (6).
To appreciate the incremental risk of any medical proce-
ure, the ambient risk of untoward outcome in the popu-
ation in question must first be defined. To our knowledge,
here are no published data on short-term major adverse
ardiac events in hospitalized patients undergoing echo-
ardiography. The purpose of this study was to define
hort-term (1-h and 24-h) mortality in a large cohort of
ospitalized patients undergoing clinically indicated echo-
ardiography, both with and without an ultrasound contrast
gent.
ethods
e performed a retrospective analysis of 18,942 consecutive
chocardiographic studies performed on hospitalized pa-
ients between January 2005 and October 2007 within the
aint Luke’s Health System, Kansas City, Missouri. During
his period, Optison was not commercially available. Pa-
ients received intravenous Definity (administered as a slow
olus of 1.5 ml Definity/8.5 ml saline) when the baseline
tudy was “technically difficult” (2 or more contiguous
yocardial segments with inadequate visualization) (1).
atients also were administered contrast agent when qual-
tative left ventricular (LV) systolic function appeared re-
uced to allow accurate and reproducible calculation of LV
jection fraction (7). For both causes, cardiac sonographers
ade the decision to administer contrast based on standing
rders. Two hundred fifty-eight patients with invalid social
ecurity numbers and 13 patients who were declared brain
ead before the echocardiogram or in whom echocardiog-
aphy was performed during a cardiac arrest were excluded
rom further analysis. The remaining 18,671 examinations
omprised the study group. These studies were separated
nto 2 groups: procedures performed without contrast en-
ancement (n 12,475) and those performed with Definity
n  6,196). Vital status within 24 h of the echocardio-
raphic study was available for all patients using a combi-
ation of the Social Security Death Master File (8) and
aint Luke’s Health System medical records. Incidence of
eath within 24 h was compared by the chi-square test
etween Definity and non-Definity procedures. Because
ome patients (n  2,589 of 14,063, 18.4%) received
ultiple procedures, a further analysis was conducted to
ccount for within-patient correlation, using repeated-
easures logistic regression with generalized estimating
quations.
Patient characteristics were obtained for a random sample
f 403 patients (202 Definity and 201 unenhanced) to
etermine the baseline demographics and clinical acuity.
ontinuous variables are reported as mean  standard
eviation and/or median and interquartile range as appro-
criate, and were compared using
tests. Categorical variables are
eported as frequency and per-
ent and were compared using
hi-square tests. Values of p 
.05 denoted statistical signifi-
ance. All analyses were con-
ucted using SAS version 9.1
SAS Institute Inc., Cary, North Carolina).
esults
aseline characteristics from a random sample of patients in
he unenhanced (n  201) and Definity (n  202) groups
re shown in Table 1. Patients who underwent Definity-
nhanced echocardiography showed higher clinical acuity
nd more significant comorbidities.
Of the 18,671 patient events, 72 patients died within
4 h. Of those who underwent unenhanced echocardiogra-
hy, 46 died within 24 h (0.37%). Of patients receiving
efinity during the echocardiogram, 26 died within 24 h
0.42%). There was no statistical difference between these 2
roups (p  0.60) (when corrected for repeated measures,
 0.62). No patient died within 1 h of the echocardio-
raphic study. Given the observed mortality rate of 0.37%
mong patients not receiving Definity, with our sample size
f 18,671 studies we would have 80% power to detect a
haracteristics of Patients Undergoingchocardiography Wi h and Without Contrastn an ement
Table 1
Characteristics of Patients Undergoing
Echocardiography With and Without Contrast
Enhancement
Echocardiography
With Contrast
(n  202)
Unenhanced
Echocardiography
(n  201) p Value
Age (yrs) 66.1 15.0 64.2 18.3 0.254
Gender 0.001
Female 72 (35.6%) 117 (58.2%)
Male 130 (64.4%) 84 (41.8%)
Hospital length of stay 0.181
Mean  SD 9.6 25.7 7.1 8.9
Median (IQR) 5.0 (3.0–8.0) 4.0 (2.0–9.0)
ICU (days) 0.007
Mean  SD 2.9 9.5 1.0 2.4
Median (IQR) 0.0 (0.0–3.0) 0.0 (0.0–1.0)
Diabetes mellitus 73 (36.3%) 37 (18.4%) 0.001
Hypertension 173 (86.1%) 118 (58.7%) 0.001
Serum creatinine 0.107
Mean  SD 1.6 1.3 1.4 1.2
Median (IQR) 1.2 (0.9–1.6) 1.1 (0.9–1.4)
Chronic obstructive lung
disease
48 (23.9%) 22 (10.9%) 0.001
Coronary artery disease 143 (71.1%) 64 (31.8%) 0.001
Stroke 37 (18.4%) 31 (15.4%) 0.425
Left ventricular ejection
fraction
48.3 15.8 58.9 12.1 0.001
ontinuous variables are reported as mean SD and/or median and IQR as appropriate, and were
ompared using t tests. Categorical variables are reported as frequency and percent and were
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
HF  heart failure
LV  left ventricularompared using chi-square tests.
ICU  intensive care unit; IQR  interquartile range.
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Ultrasound Contrast Safety April 29, 2008:1704–6efinity mortality rate of 0.68%, corresponding to a relative
isk of 1.84.
The primary cause of death was determined by review of
edical records and included sepsis (n  14), acute myo-
ardial infarction/ACS (n 10), HF (n 8), pneumonia or
hronic lung disease (n 8), cancer (n 5), stroke (n 5),
ost-operative complications (n  4), intracranial hemor-
hage (n  3), ruptured intra-abdominal aortic aneurysm
n  2), pulmonary embolism (n  2), pulmonary hyper-
ension (n  1), and miscellaneous causes (n  10). In the
atients who died within 24 h of Definity administration,
here was no evidence for acute allergy or anaphylaxis.
eview of hospital medical records in the 202 randomly
elected Definity patients showed that 56% (n  114) had
or more of the new contraindications to contrast admin-
stration (ACS, worsening or decompensated HF, or respi-
atory failure).
To determine the clinical utility of contrast in this
opulation, an experienced echocardiographer reviewed the
03 echocardiograms in the random sample. Endocardial
esolution was graded as adequate or suboptimal for each of
6 myocardial segments (9). The mean number of ade-
uately visualized segments was 13.5 for the unenhanced
roup, 10.1 for the pre-contrast images in the Definity
roup, and 14.4 for the contrast-enhanced Definity images
p  0.0001 for the Definity group comparisons). Patho-
ogical findings, including LV apical mural thrombus (n 
), LV apical aneurysm (n  1), and LV apical ballooning
n  1), were identified in the Definity group.
iscussion
he recently issued boxed warning and new contraindica-
ions for ultrasound contrast agents were largely based on
ost-marketing reports of 4 deaths that were temporally
elated to, but not clearly causally attributable to, Defin-
ty administration. As outlined in a recent publication
6), untoward outcomes after a medical procedure may be
ttributable to the procedure itself (complication) or
rogression of the underlying disease state (pseudocom-
lication).
In this study, unenhanced echocardiography was associ-
ted with a 0.37% acute (24-h) mortality rate in hospitalized
atients. This should not be surprising because echocardi-
graphy is frequently performed in those who are most
ritically ill. Contrast-enhanced echocardiography was not
ssociated with any increased mortality risk. Given theigher clinical acuity and more comorbid conditions in the
ontrast-enhanced group, we believe these data represent a
ery conservative estimate of contrast echocardiography
afety.
onclusions
pproximately 0.4% of hospitalized patients die within 24 h
f echocardiography. There is no increased mortality risk
ssociated with Definity-enhanced echocardiographic ex-
minations in hospitalized patients, despite evidence for
igher clinical acuity and more comorbid conditions in
atients undergoing contrast-enhanced studies.
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